Update
$Ocugen (OCGN.US)$ Reuters· just
Ocugen Announces Compelling Preliminary Data for Ocu410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Ocugen Announces Compelling Preliminary Data for Ocu410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Trytosaveabit OP : Findings Included No Drug-related Serious Adverse Events, Reduced Lesion Growth, Preservation Of Retinal Tissue, Positive Effect On The Functional Visual Measure Of Low Luminance Visual Acuity